Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drug
Plus, news about Merus, Supernus and Verrica:
Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
